- $28.57m
- $29.30m
- $1.27m
Cannabis stocks climb after Trump signs order to ease curbs on marijuana (updated)
Cannabis stocks rise ahead of potential Trump order to ease marijuana restrictions
Brief: IGC Pharma's Unit Enters Sale Of Assets Agreement For $2.7 Million - SEC Filing
Brief: IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment
IGC maintains global wheat, corn production forecasts (updated)
Brief: Igc Pharma Announces Additional Data Supporting Igc-Ad1 As An Alzheimer's Treatment
Brief: IGC Pharma Advances IGC-AD1 Toward Clinical Trials As A Potential Anti-Amyloid Plaque Treatment For Alzheimer's Disease
U.S. RESEARCH ROUNDUP-Adapthealth, Carnival, Phunware
Brief: IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease
Brief: IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist
U.S. RESEARCH ROUNDUP-Edwards Lifesciences, National Bank Holdings, Sage Therapeutics
Brief: Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
Brief: IGC Pharma's Tgr-63 Preclinical Results Show Substantial Reduction In Amyloid Plaque, A Key Hallmark Of Alzheimer's Disease
Brief: IGC Pharma Announces Patient Enrollment At Neurostudies In Phase 2 Trial Investigating Igc-Ad1
Brief: IGC Pharma Announces Positive Interim Results For IGC-AD1 In Reducing Alzheimer’S Agitation
Brief: Igc Pharma Says Entered Into New Sales Deal With Alliance Global Partners, Co May Offer And Sell, From Time To Time Shares Of Common Stock
Brief: Igc Pharma Breakthrough Preclinical Trial Data Shows Tgr-63 Reduces Plaque In Alzheimer’S
Brief: IGC Pharma Files For Mixed Shelf Offering Of Up To $100 Million
Brief: Igc Pharma Inc- Divisional Direction Of Patents, Mexico, Has Issued A Granting Office Action (Goa) For Its Treatment Of Alzheimer's Disease